Listed

Champions Oncology, Inc.: Form 10-Q for the period ended Jul 31, 2017

Filed with the SEC on Sep 14, 2017 and accepted by EDGAR at Sep 14, 2017, 17:22 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-07-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2017-05-01 to 2017-07-31$1.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-05-01 to 2017-07-31−$619.0kus-gaap:OperatingIncomeLoss
Income tax3 months2017-05-01 to 2017-07-31$4.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2017-05-01 to 2017-07-31−$674.2kus-gaap:NetIncomeLoss
Operating cash flow3 months2017-05-01 to 2017-07-31−$1.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2017-05-01 to 2017-07-31$910.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2017-07-31$430.0kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-07-31$3.5mus-gaap:AssetsCurrent
Total assetsAt period end2017-07-31$6.5mus-gaap:Assets
Current liabilitiesAt period end2017-07-31$6.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-07-31$6.2mus-gaap:Liabilities
Shareholders' equityAt period end2017-07-31$290.0kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001628280-17-009317. Last ingested by Listed: Nov 10, 2026, 03:33 ET. Listed shows no prices and gives no investment advice.